HRMY
Harmony Biosciences Holdings, Inc.
$35.77
-0.24
(-0.67%)
Mkt Cap
2.07B
Volume
882,096
52W Range
25.52-40.87
Sector
Healthcare
Beta
0.94
EPS (TTM)
2.52
P/E Ratio
14.19
Revenue (TTM)
899.11M
Rev Growth (5Y)
+40.3%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$137.37
Undervalued
strong signal
74.0% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
A-
Platform & Compounding FCF
80.6 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 868.45M | 714.73M | 582.02M | 437.86M | 305.44M | 159.74M | 6.00M | 0 |
| Net Income | 158.69M | 145.49M | 128.85M | 181.47M | 34.60M | (36.94M) | (151.98M) | (39.90M) |
| EPS | 2.76 | 2.56 | 2.17 | 3.07 | 0.60 | -1.12 | -2.94 | -1.42 |
| Free Cash Flow | 347.89M | 218.67M | 219.07M | 144.29M | 98.26M | (4.99M) | (75.58M) | (40.14M) |
| FCF / Share | 6.05 | 3.84 | 3.68 | 2.44 | 1.71 | -0.09 | -1.19 | -0.82 |
| Operating CF | 348.20M | 219.82M | 219.39M | 144.47M | 98.56M | (2.98M) | (75.44M) | (38.80M) |
| Total Assets | 1.27B | 999.20M | 811.45M | 673.87M | 433.44M | 427.07M | 106.70M | 89.28M |
| Total Debt | 239.58M | 181.41M | 193.57M | 191.65M | 195.74M | 194.25M | 97.95M | 324.20M |
| Cash & Equiv | 752.50M | 453.00M | 311.66M | 243.78M | 234.31M | 228.63M | 24.46M | 83.52M |
| Book Value | 870.22M | 659.15M | 466.99M | 402.84M | 186.51M | 97.18M | (11.59M) | 81.53M |
| Return on Equity | 0.18 | 0.22 | 0.28 | 0.45 | 0.19 | -0.38 | N/A | -0.49 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 215.39M | 243.78M | 239.46M | 200.49M | 184.73M | 201.27M | 186.04M | 172.81M | 154.62M | 168.41M | 160.27M | 134.22M |
| Net Income | 32.49M | 22.49M | 50.87M | 39.78M | 45.56M | 49.48M | 46.09M | 11.59M | 38.33M | 26.61M | 38.46M | 34.30M |
| EPS | 0.56 | 0.39 | 0.88 | 0.69 | 0.80 | 0.87 | 0.81 | 0.20 | 0.68 | 0.46 | 0.64 | 0.57 |
| Free Cash Flow | 27.76M | 126.04M | 108.66M | 79.32M | 33.86M | 75.05M | 70.50M | 41.98M | 31.14M | 76.56M | 63.10M | 36.86M |
| FCF / Share | 0.48 | 2.19 | 1.86 | 1.38 | 0.59 | 1.31 | 1.24 | 0.74 | 0.55 | 1.31 | 1.05 | 0.61 |
| Operating CF | 27.76M | 126.15M | 108.73M | 79.33M | 33.99M | 75.56M | 70.50M | 42.62M | 31.14M | 76.67M | 63.10M | 37.06M |
| Total Assets | 1.27B | 1.27B | 1.21B | 1.11B | 1.06B | 999.20M | 928.13M | 858.38M | 846.99M | 811.45M | 777.77M | 760.18M |
| Total Debt | 206.51M | 239.58M | 169.73M | 173.37M | 177.46M | 181.41M | 185.24M | 189.06M | 193.06M | 196.09M | 199.72M | 193.72M |
| Cash & Equiv | 589.40M | 752.50M | 647.00M | 546.05M | 489.00M | 453.00M | 387.37M | 317.30M | 332.98M | 311.66M | 324.60M | 317.42M |
| Book Value | 910.35M | 870.22M | 835.12M | 773.08M | 720.52M | 659.15M | 596.80M | 538.58M | 515.39M | 466.99M | 481.33M | 485.17M |
| Return on Equity | 0.04 | 0.03 | 0.06 | 0.05 | 0.06 | 0.08 | 0.08 | 0.02 | 0.07 | 0.06 | 0.08 | 0.07 |
HRMY News
5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfolio
Harmony Biosciences: WAKIX Cash Flow Funds Its Own Disruption
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
HRMY vs. AMGN: Which Stock Is the Better Value Option?